Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer

Overview

About this study

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Patients must have undergone complete surgical resection of their stage IB (≥4 cm), II or IIIA NSCLC according to the AJCC 7th edition (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351680/) and have had negative surgical margins.
  • Baseline chest CT must be performed within 1 month (30 days) prior to randomization to ensure no evidence of disease. If clinically indicated, additional imaging studies must be performed to rule out metastatic disease.
  • ECOG performance status 0-1.
  • Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization.
  • Non-squamous tumors must not be positive for EGFR Exon 19 deletion or Exon 21 L858R mutation (centrally as part of the ALCHEMIST-SCREEN protocol) and ALK rearrangement (centrally as part of ALCHEMIST-SCREEN and/or locally, see NOTE below).
    • NOTE: If the results of the central EGFR testing are negative, but the ALK testing was not able to be completed by the ALCHEMIST central lab, the ALK status will be considered negative (unless locally positive for ALK rearrangement) and the patient may be considered for enrollment onto EA5142, once PD-L1 results are received and all other eligibility requirements are met.
  • Tumors must have PD-L1 status tested centrally as part of the ALCHEMIST-SCREEN protocol.
  • Women must not be pregnant or breast-feeding due to unknown and potentially harmful effects of nivolumab on the developing fetus or child.
  • All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.  A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
    • Female of child bearing potential? ______ (Yes or No)
    • Date of blood test or urine study: ___________
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse during the treatment period and for 31 weeks after the last nivolumab infusion.
  • Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
  • No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA4 monoclonal antibody).
  • Patients must have adequately recovered from thoracic surgery and any administered chemotherapy/radiotherapy at the time of randomization.
    • NOTE: adjuvant chemotherapy and/or radiation is not required)
  • Minimum time between date of surgery and randomization is 4 weeks (28 days).
  • Maximum time allowed between surgery and randomization:
    • 3 months (90 Days) if no chemotherapy is administered.
    • 8 months (240 Days if adjuvant chemotherapy was administered.
    • 10 months (300 Days) if adjuvant chemotherapy and radiation therapy was administered.
  • Patients must have completed and recovered from any adjuvant chemotherapy 2 or more weeks prior to randomization (6 weeks for mitomycin and nitrosoureas; 4 weeks for post-operative radiation therapy). (NOTE: adjuvant chemotherapy and/or radiation is not required)
  • Patients must have adequate organ function as defined by the following criteria within 2 weeks prior to randomization:
    • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit normal
    • AST:_____________Date of Test:______________
    • ALT:_____________Date of Test:______________
    • Total bilirubin ≤ 1.5 x ULN (except in subjects with Gilbert Syndrome who must have a total bilirubin < 3.0xULN)
    • Giblert syndrome: yes/no
    • Total bilirubin:____________Date of Test:__________
    • 3.1.15.3 WBC ≥ 2000/μL
    • WBC:___________Date of Test:__________
    • 3.1.15.4 Neutrophils ≥ 1000/μL:
    • Neutrophils:________Date of Test:__________
    • 3.1.15.5 Platelets ≥ 100x103/μL
    • Platelets:__________Date of Test:__________
    • 3.1.15.6 Hemoglobin ≥ 8 g/dL
    • Hemoglobin:_______Date of Test:__________
    • 3.1.15.7 Serum creatinine ≤ 2xULN
    • Creatinine:__________Date of Test:__________
  • Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to Grade ≤ 1 with the exception of alopecia, ototoxicity and neuropathy.
  • Patients must not be receiving any other investigational anti-cancer agents while on study.
  • Patients must not have known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll.
  • Patients must not have a condition requiring systemic corticosteroids equivalent to >10 mg prednisone per day or other immunosuppressive medications within 2 weeks of randomization. Inhaled, intra-articular, and epidural steroids are permissible.
  • Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  • Patients must not have a known history of HIV, hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load.
  • Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.

 

 

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aaron Mansfield, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Panayiotis Savvides, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions